BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioMarin Announces Second Quarter 2015 Financial Results and Company Update
August 3, 2015 4:02 PM EDT- In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y - First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of Achondroplasia
Financial Highlights ($ in millions, except per share data, unaudited)
 Three Months Ended June 30, Six Months Ended June 30,  2015 2014 % Change 2015 2014 % Change        Total BioMarin Revenue  $ 250.5  $ 191.8 31%  $ 453.8  $ 343.3 32% Vimizim Net Product Revenue  53.9  14.3 n.m.  104.5... More